

# LIPID-LOWERING EFFECT OF TENOFOVIR IN PATIENTS WITH CHRONIC HEPATITIS B

J. Sánchez-Rubio Ferrández, C. Apezteguía Fernández, E. Matilla García, M.P. Bautista Sanz, E. Fernández Esteban, R. Moreno Díaz.

Hospital Universitario Infanta Cristina, Pharmacy Department, Parla (Madrid), Spain.

Some studies have suggested a lipid-lowering effect of tenofovir (TDF) in HIV infected patients who take antiretroviral therapy.



## PURPOSE

To assess lipid-lowering effect of TDF in patients with chronic hepatitis B (CHB)

## MATERIALS AND METHODS

- Retrospective single-institution study.
- Inclusion criteria: adults with CHB, not HIV-coinfected, treated with tenofovir for at least one month.
- Demographic and treatment data (prior antiviral treatment, lipid-lowering therapy) were collected
- Total cholesterol (TC)** and **triglycerides** basal values were compared with those obtained 3-6 months after treatment onset.
- Mean values were compared using two-tailed Student's test.

## RESULTS

18 patients included. Ten patients (56%) were male. Mean ( $\pm$ SD) age was  $47,7\pm 10,8$  years. None of the patients took lipid-lowering agents at baseline or during the study. Seven patients (38,9%) received other hepatitis B treatment before tenofovir.

	Basal	After tenofovir	
TC	202,4 $\pm$ 38,9	174,6 $\pm$ 30,9	p=0,001
Triglicerides	96,2 $\pm$ 45,2	97,2 $\pm$ 49,2	p=0,917

Sixteen patients (89%) improved TC levels.

## CONCLUSIONS

- TC decreased significantly over the study period for most patients
- TDF did not seem to have a positive effect on triglycerides